Gene Therapy of the $\beta$-Hemoglobinopathies by Lentiviral Transfer of the $\beta^A(T87Q)$-Globin Gene

Olivier Negre,1,2,* Anne-Virginie Eggimann,1 Yves Beuzard,2,3 Jean-Antoine Ribeil,4 Philippe Bourget,4 Suparerk Borwornpinyo,5 Suradej Hongeng,5 Salima Hacein-Bey,5 Marina Cavazzana,4 Philippe Leboulch,2,3,5,7 and Emmanuel Payen2,3,8,*

1bluebird bio, Cambridge, Massachusetts; 2CEA, Institute of Emerging Disease and Innovative Therapies (iMETI), Fontenay aux Roses, France; 3UMR 007, University of Paris 11 and CEA, CEA-iMETI, Fontenay aux Roses, France; 4Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; 5Mahidol University, Bangkok, Thailand; 6Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Assistance Publique-Hôpitaux de Paris, Paris, France; 7Harvard Medical School and Genetics Division, Department of Medicine, Brigham & Women’s Hospital, Boston, Massachusetts; 8INSERM, Paris, France.

*Correspondence: Dr. Emmanuel Payen, CEA/iMETI, 18 route du Panorama, 92260 Fontenay aux Roses, France. E-mail: emmanuel.payen@cea.fr or Dr. Olivier Negre, bluebird bio, 150 Second Street, Cambridge, MA 02141. E-mail: onegre@bluebirdbio.com

© Olivier Negre et al. 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

$\beta$-globin gene disorders are the most prevalent inherited diseases worldwide and result from abnormal $\beta$-globin synthesis or structure. Novel therapeutic approaches are being developed in an effort to move beyond palliative management. Gene therapy, by ex vivo lentiviral transfer of a therapeutic $\beta$-globin gene derivative ($\beta^A(T87Q)$-globin) to hematopoietic stem cells, driven by cis-regulatory elements that confer high, erythroid-specific expression, has been evaluated in human clinical trials over the past 8 years. $\beta^A(T87Q)$-globin is used both as a strong inhibitor of HbS polymerization and as a biomarker. While long-term studies are underway in multiple centers in Europe and in the United States, proof-of-principle of efficacy and safety has already been obtained in multiple patients with $\beta$-thalassemia and sickle cell disease.

INTRODUCTION

Sickle cell disease (SCD) and $\beta$-thalassemia major ($\beta$-TM), the latter defined clinically as transfusion-dependent cases regardless of the underlying genotype, are the most common monogenic disorders worldwide with approximately 400,000 affected conceptions or births each year.1,2 These disorders fall into two large groups of $\beta$-globin gene mutations that result in either abnormal hemoglobin structure (SCD) or massively reduced/absent production of $\beta$-globin chains ($\beta$-TM). The clinical manifestations of these inherited disorders typically appear several months after birth, when gene expression switches from the fetal $\gamma$-globin chain, which forms fetal hemoglobin (HbF), to the adult $\beta^A$-globin chain forming hemoglobin (HbA).3 Note that adult $\beta^A$-globin is also simply referred to as $\beta$-globin when no confusion with other $\beta$-like globin chains is possible. In low-income countries, most of the affected children succumb in early childhood, whereas in developed countries, neonatal diagnosis and supportive care have greatly improved survival. However, even with modern and specialized care, life expectancy is still reduced by several decades,4–6 and quality of life greatly suffers.7–9

Allogenic hematopoietic stem cell transplantation (AHSCT) as a curative option is currently recommended for $\beta$-TM if a human leukocyte antigen (HLA)-matched sibling donor is available.10,11 Disease-free survival after AHSCT is approximately 88% in pediatric subjects12 and 65% in adults.13 Recent transplantation trials conducted during the last 15 years for young SCD patients reported a disease-free survival rate of 85–90%.11 However, fewer than 25% of patients have a suitable intrafamilial donor.14 In the absence of matched sibling donors, AHSCT from HLA-matched unrelated or haploidentical donors or minimally mismatched cord blood products may be used as the source of donor cells, although these approaches exhibit a lower benefit/risk ratio and thus remain experimental.15 Although outcomes are improving, AHSCT continues to carry a substantial risk
of severe adverse events and mortality,\textsuperscript{16,17} both increasing with recipient age and disease severity.\textsuperscript{18,19} Severe adverse events include graft failure, graft-versus-host disease (GVHD), early or late side effects from conditioning regimens that are both myeloablative and immunosuppressive (infections, hemorrhages, secondary malignancies), and aggravation of preexisting organ damage.\textsuperscript{20–22}

For patients who lack a suitable HLA-matched donor, \textit{ex vivo} gene therapy using autologous HSCs brings hope as a potential curative treatment option. If proven safe and effective, gene therapy may then be extended to most \(\beta\)-TM and severe SCD patients, as there is no concern here for histocompatibility-related complications and the conditioning regimen does not need to include immunosuppressive drugs. However, gene therapy shares with AHSCT the risks associated with the transplant procedure and the toxicity of the myeloablative agent. \textit{Globin} gene addition to HSCs by means of lentiviral vectors (LVs) is a promising approach under investigation (Fig. 1). Several clinical trials of gene therapy for \(\beta\)-TM and severe SCD are ongoing in France and in the United States (Tables 1 and 2). Other recent approaches under study for the gene therapy of the \(\beta\)-hemoglobinopathies include pharmacological\textsuperscript{23} or genetic induction of \(\gamma\)-globin production through interference with the BCL11A pathway\textsuperscript{24,25} or disruption of the BCL11A erythroid enhancer by CRISPR/CAS9 technology as well as zinc finger or transcription activator-like effector nuclease,\textsuperscript{26,27} or even attempts at repairing the defective \(\beta^A\)-globin gene in HSCs by genome editing.\textsuperscript{28–30} These approaches are at the stage of collecting evidence of efficacy in relevant cell and animal models and scoring potentially untoward off-target events. Even if these approaches are ultimately successful, gene addition has the advantage of making use of a single product applicable to all cases of \(\beta\)-TM and SCD regardless of the genotype, whereas gene repair will have to tackle separately the hundreds of mutations known to cause \(\beta\)-thalassemia in humans.

While we recognize the important contributions from other laboratories, this review will largely focus on our own experience with the development of the HPV569 and BB305 vectors, self-inactivating (SIN) LVs bearing a human \(\beta^A\)-globin mini-gene encoding an “antisickling” \(\beta\)-globin with amino-acid substitution (T87Q) and driven by cis-regulatory elements of the human \(\beta\)-globin gene locus (promoter, locus control region [LCR] elements), designed in the Leboulch laboratory in collaboration with bluebird bio (formerly Genetix Pharmaceuticals).

\section*{THE \(\beta\)-HEMOGLOBINOPATHIES}

\textbf{The \(\beta\)-thalassemias}

\(\beta\)-TM is a microcytic hemolytic anemia that is rapidly fatal in the absence of palliative life-long red blood cell (RBC) transfusions and iron chelation.\textsuperscript{31} The disease results from absence (\(\beta^0\)) or massive reduction (e.g., \(\beta^+\), \(\beta^E/\beta^0\)) in \(\beta^A\)-globin gene expression. While complete absence of \(\beta^A\)-globin expression is not compatible with RBC production, even a severe diminution in its expression also re-

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{The milestones of \textit{ex vivo} gene therapy research and development for hemoglobin disorders. LG001, HGB204, HGB205, and HGB206 clinical studies are conducted with our lentiviral vectors (Table 1). Gene therapy trials using other lentiviral vectors are summarized in Table 2.}
\end{figure}
<table>
<thead>
<tr>
<th>Gene</th>
<th>Vector</th>
<th>Location</th>
<th>Protocol number</th>
<th>Sponsor</th>
<th>Condition</th>
<th>Conditioning</th>
<th>Intervention</th>
<th>Phase</th>
<th>Title</th>
<th>Start date</th>
<th>Results as of December 2015</th>
<th>Estimated primary completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-A-T87Q-globin</td>
<td>HPV569</td>
<td>France</td>
<td>LG001 study</td>
<td>bluebird bio (formerly Genetix Pharmaceuticals)</td>
<td>β-thalassemia major and severe sickle cell disease</td>
<td>Myeloablative conditioning</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I/II</td>
<td>A Phase I/II Open Label Study with Anticipated Benefit Evaluating Genetic Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Modified ex vivo with a Lentiviral βA-T87Q Globin (LentiGlobin™) Vector</td>
<td>Sept 2006</td>
<td>First βE/β0-treated patient in the world, independent of transfusions for more than 7 years</td>
<td>Terminated</td>
</tr>
<tr>
<td>β-A-T87Q-globin</td>
<td>BB305</td>
<td>France</td>
<td>NCT02151526 (HGB-205 study)</td>
<td>bluebird bio</td>
<td>β-thalassemia major and severe sickle cell disease</td>
<td>Myeloablative conditioning</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I/II</td>
<td>A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Modified ex vivo with a Lentiviral βA-T87Q-Globin Vector (LentiGlobin™ BB305 Drug Product)</td>
<td>July 2013</td>
<td>First βS/βS-treated patient in the world, with &gt;50% βE/β0 patients independent of transfusions, 1 β0/β0 treated recently</td>
<td>December 2017</td>
</tr>
<tr>
<td>β-A-T87Q-globin</td>
<td>BB305</td>
<td>USA, Thailand, Australia</td>
<td>NCT01745120 (HGB-204 study)</td>
<td>bluebird bio</td>
<td>β-Thalassemia major</td>
<td>Myeloablative conditioning</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I/II</td>
<td>A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Modified ex Vivo with a Lentiviral βA-T87Q-Globin Vector (LentiGlobin™ BB305 Drug Product)</td>
<td>August 2013</td>
<td>10 subjects infused: 5 β0/β0, 3 β0/βE, 1 β0/β+, and 1 with another genotype Transfusion independence for the majority</td>
<td>September 2017</td>
</tr>
<tr>
<td>β-A-T87Q-globin</td>
<td>BB305</td>
<td>USA</td>
<td>NCT02140554 (HGB-206 study)</td>
<td>bluebird bio</td>
<td>Severe sickle cell disease</td>
<td>Myeloablative conditioning</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I</td>
<td>Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease</td>
<td>August 2014</td>
<td>3 βS/βS subjects treated. No clinical results available yet</td>
<td>March 2019</td>
</tr>
</tbody>
</table>

Results were given at several international meetings. 159, 163, 164
<table>
<thead>
<tr>
<th>Gene</th>
<th>Vector</th>
<th>Location</th>
<th>Protocol number</th>
<th>Sponsor</th>
<th>Condition</th>
<th>Conditioning</th>
<th>Intervention</th>
<th>Phase</th>
<th>Title</th>
<th>Start date</th>
<th>Results</th>
<th>Estimated primary completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-globin</td>
<td>TNS9.355</td>
<td>USA</td>
<td>NCT01638690</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>β-Thalassemia major</td>
<td>Partial cytoducton (Bu 8 mg/kg) for 3 patients, myeloablative conditioning (Bu 14 mg/kg) for 1 patient</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I</td>
<td>A Phase I Clinical Trial for the Treatment of β-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells Transduced with TNS9.355 a Lentiviral Vector Encoding the Normal Human β-Globin Gene</td>
<td>July 2012</td>
<td>Four patients treated. Three β0/β+ and one β0/β0. One patient had a significant decrease in transfusion requirements.</td>
<td>July 2016</td>
</tr>
<tr>
<td>γ-globin</td>
<td>sGbG</td>
<td>USA</td>
<td>NCT02186418</td>
<td>Children’s Hospital Medical Center, Cincinnati</td>
<td>Severe sickle cell disease</td>
<td>Unknown</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I/II</td>
<td>Gene Transfer for Patients with Sickle Cell Disease Using a Gamma Globin Lentivirus Vector: An Open Label Phase I/II Pilot Study</td>
<td>July 2014</td>
<td>No results available yet</td>
<td>July 2017</td>
</tr>
<tr>
<td>γAS3-globin (T87Q, G16D, E22A)</td>
<td>Lenti/γAS3-FB</td>
<td>USA</td>
<td>NCT02247843</td>
<td>University of California, Children’s Hospital, Los Angeles</td>
<td>Severe sickle cell disease</td>
<td>Unknown</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector</td>
<td>I</td>
<td>Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified with the Lenti/γAS3-FB Lentiviral Vector</td>
<td>August 2014</td>
<td>No results available yet</td>
<td>April 2017</td>
</tr>
<tr>
<td>β-globin</td>
<td>GLOBE</td>
<td>Italy</td>
<td>NCT02453477</td>
<td>IRCCS San Raffaele</td>
<td>β-Thalassemia major</td>
<td>Myeloablative conditioning</td>
<td>Transplantation of HSCs transduced ex vivo with a lentiviral vector (intrabone injection)</td>
<td>I/II</td>
<td>A Phase II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector Encoding for the Human Beta Globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-Thalassemia</td>
<td>May 2015</td>
<td>First patient recently treated</td>
<td>August 2019</td>
</tr>
</tbody>
</table>

*Clinic-altrials.gov
Results were provided at international meetings.165,166
results in $\beta$-TM. This is because the protein component of adult hemoglobin comprises two $\alpha$- and two $\beta$-globin chains, and massive decrease in $\beta$-globin expression results in a relative excess of unpaired and toxic free $\alpha$-chains. Free $\alpha$-chains precipitate, damage the cell membrane, and sequester the chaperone heat shock protein 70 (HSP70), which is no longer available to protect the GATA-1 erythroid maturation transcription factor from caspase-3 cleavage. $\alpha/\beta$-chain imbalance results in cell death and ineffective erythropoiesis (dyserythropoiesis) in bone marrow as well as reduced erythrocyte lifespan and hemolysis.

Among the severe $\beta$-thalassemias, the $\beta^E/\beta^0$ genotype presents interesting features and is highly frequent. In this disease, one $\beta$-globin allele is completely silent ($\beta^0$) while the other encodes the missense mutation (26AAG>GAG) that results both in an amino-acid substitution (GLU26LYS) and in abnormal RNA splicing. Part of the transcribed $\beta^E$ mRNA is not translated because of abnormal splicing, whereas the small amount of mutated (GLU26LYS) protein produced is functional but slightly unstable. Thus, when the $\beta^E$ allele is compounded with a $\beta^0$ allele, a profound decrease in $\beta$-like globin production is observed. Approximately 50% of patients with $\beta^E/\beta^0$-thalassemia have transfusion-dependent $\beta$-TM, depending on the patient’s genetic makeup in modulators of disease severity. Hemoglobin E is one of the world’s most common mutations and is especially prevalent in Southeast Asia. The frequency can approach 60% of the population in some parts of Thailand, Cambodia, and Laos, where it is estimated that 100,000 new cases of the disease are expected in the next few decades. It is also found at high frequency in other Asian nations (India, Sri Lanka, Malaysia, and southern China) and increasingly in Europe and North America through immigration.

**SCD cell disease**

SCD is a multisystem disorder that results from a single mutation in the $\beta^A$-globin gene, changing a glutamic acid into a valine at the sixth position of the $\beta$-globin chain, known as the $\beta^S$ mutation. In homozygous patients ($\beta^S/\beta^S$), the most frequent genotype, or in the compound heterozygous states ($\beta^S/\beta^C$, $\beta^S/\beta^E$-thalassemia) of SCD, the chronic hemolytic anemia is complicated by painful vaso-occlusive crises (VOC), acute chest syndrome (ACS), increased risk of infections, as well as organ vasculopathy and dysfunctions, particularly affecting brain, kidney, lung, heart, bone, eye, and the skin.

At the protein level, the single amino-acid substitution at codon 6 ($\beta^S$ chain) prompts the formation of HbS polymers at low oxygen pressure, the rate of which is proportional to the corpuscular concentration of HbS, the extent of hemoglobin deoxygenation in the microcirculation, and the quantity of HbF, which inhibits HbS polymerization. Vaso-occlusion, resulting from erythrocyte stiffness and the adhesive interaction of abnormal erythrocytes to endothelial cells and leukocytes, leads to organ infarction and inflammation, which in turn enhances adhesive interactions, microvascular occlusion, and ischemia. The increased number of activated white blood cells produces high levels of reactive oxygen species (ROS) and other factors contributing actively to micro-vessel clogging, increased local hypoxia, and increased proportions of rigid RBCs containing HbS polymers.

The cycles of ischemia/reperfusion cause oxidative stress that contributes to the proinflammatory phenotype, worsening the vicious circle. Furthermore, acute and chronic intravascular hemolysis impairs endothelial functions, causing progressive systemic and pulmonary vasculopathy.

**CHALLENGES FOR EFFECTIVE GENE THERAPY**

**The therapeutic $\beta^{6A(T87Q)}$-globin gene**

With regard to the gene therapy of SCD by gene addition, wild-type human $\beta^A$-globin is a relatively weak inhibitor of HbS polymerization because it acts by mere dilution. When PO2 is relatively low, as in capillary vessels, phenylalanine 85 ($\beta^{85}$) and leucine 88 ($\beta^{88}$) form an acceptor hydrophobic pocket on one $\alpha^2$, $\beta^2$ tetramer that binds to the mutated valine ($\beta^{V6}$) of a close $\alpha^2$, $\beta^2$ complex. This phenomenon is responsible for HbS fiber polymerization after further aggregation and fiber elongation. HbA ($\alpha^2, \beta^2$) has these same hydrophobic residues and thus does not inhibit polymer formation when it is incorporated.

In contrast, other human $\beta$-like$^$-globin chains such as $\gamma$-globin and $\delta$-globin are stronger inhibitors. This inhibition of polymerization is best exemplified by cases of hereditary persistence of HbF (HPFH), especially of the pan-cellular type (within all erythrocytes), where as little as 20% HbF is sufficient to inhibit HbS formation in vivo and to alleviate substantially the clinical manifestations of SCD in homozygous $\beta^S/\beta^S$ patients. In these cases, the $\gamma$-chain excludes the heterotetramer $\alpha^2, \gamma^2$ from the HbS polymer.

However, neither $\gamma$- nor $\delta$-globin genes are highly expressed in the “adult” (postglobin switch) RBC environment. Because the $\beta^A$, $\gamma$, and $\delta$-globin chains are co-linear and comprise only a few dif-
ferences in amino-acid residues between them, especially between $\beta^A$ and $\delta$ with only 10 differences out of 146, biochemical studies were performed to determine which positions were critical to inhibit HbS polymerization. Within the acceptor hydrophobic pocket, a critical residue differs at position 87 between $\beta^A$ (T87) and $\gamma$ or $\delta$ (Q87), and has been determined to be responsible for most of the inhibitory effect of $\gamma$- or $\delta$-globins on HbS polymerization. A few other residues co-contribute to a lesser degree, and in particular Ala-22. In an effort to express a strong antisickling $\beta$-globin derivative at high levels in adult RBCs, a modified $\beta^A$-globin gene was designed (Leboulch Laboratory) that comprises a point mutation within a human $\beta$-globin minigene suitable for retroviral transfer, so that the expressed therapeutic protein is $\beta^{A(T87Q)}$. The resulting $\beta^{A(T87Q)}$-globin chain appears as efficient as $\gamma$-globin to inhibit HbS polymerization in biochemical assays. The oxygen affinity of the mutated tetramer (HbAT87Q: $\alpha_2\beta^{A(T87Q)}$) is in the range of that of HbA, whereas the oxygen affinity of HBF is substantially higher than that of HbA.

Furthermore, the $\beta$-globin T87Q is a valuable biomarker of biological efficacy in human clinical trials. The $\beta^{T87Q}$-globin chain can be distinguished and quantified from $\beta^A$ and $\gamma$-globins chains by high-performance reverse-phase liquid chromatography (HPLC). In the case of $\beta^A$-thalassemia or when RBC transfusions are still provided, there would otherwise be no possibility of quantifying vector-derived gene expression if wild-type $\beta^A$-globin was used as the therapeutic gene.

**Therapeutic levels of $\beta^{A(T87Q)}$-globin gene expression**

The threshold level of therapeutic $\beta^{A(T87Q)}$-globin expression required for effective gene therapy of $\beta$-TM will vary depending on residual levels, if any, of endogenous $\beta$-globin production. It will also depend on genetic modulators that contribute to reducing the severity of the disease in each individual patient. These modulators include associated $\alpha$-thalassemia or the ability to produce substantial amounts of $\gamma$-globin after birth, both reducing the magnitude of free $\alpha$-chains in erythroid cells and the severity of the disease.

With respect to SCD, one can surmise that the antisickling properties of $\beta^{A(T87Q)}$-globin will be comparable to or slightly lower than that of $\gamma$-globin. HPFH with HbF levels of 30% or even lower are consistently associated with complete absence of clinical and biological signs of SCD in otherwise homozygous $\beta^S/\beta^S$ patients, when HbF expression is well distributed among RBCs (pancellular HPFH). When HbF distribution is more heterogeneous, the antisickling effect is less pronounced, although SCD symptoms of homozygous $\beta^S/\beta^S$ were alleviated in a few reported cases of stable mixed chimerism as low as 11% after AHST. It is thus likely that expression of $\beta^{A(T87Q)}$-globin between 20% and 30%, preferably with moderate variation in expression will meet the minimum threshold to prevent most of the clinical manifestations and complications of SCD in homozygous $\beta^S/\beta^S$ patients.

**Cis-regulatory control elements to be incorporated in vectors**

Most of the genetic elements that control tissue specificity and developmental switching of $\beta$-globin gene expression are located within or near the transcription unit in the promoter region, downstream of the polyadenylation signal, and within the second intron. Nevertheless, introducing these elements to control $\beta$-globin gene expression in gamma-retroviral vectors ($\gamma$-RV) has resulted in very low levels of human $\beta$-globin gene expression in erythroid cells of mice transplanted with transduced HSCs. The discovery of chromatin domains, referred to as DNase I hypersensitive sites (HS), several kilobases upstream of the $\beta$-globin gene, has shed light on the regulatory organization of the locus. The ability of the 15 kb LCR to confer physiological levels of human $\beta$-globin, when inserted immediately 5’ to the $\beta$-globin gene in transgenic mice, has yielded clues for designing effective expression systems. The most important HS sites to cis-link to the human $\beta$-globin gene are HS2, HS3, and HS4 that have enhancer activity when tested individually in cell culture and in transgenic mice. Several laboratories have undertaken to reduce the size of each of the HS sites while maintaining most of their enhancer effect. However, while the so-called “core elements” of 250–350 bp long show useful activity when combined in $\gamma$-RV expanded elements appear necessary for near-optimal enhancer effect.

**Gene transfer vectors suitable for the gene therapy of the $\beta$-hemoglobinopathies**

Sustained gene therapy of inherited hematological disorders by ex vivo gene addition requires integration of the vector in the chromosomes of HSCs to obtain proper replication and segregation in the daughter cells for the lifespan of the recipient. To date, only retroviral vectors have reproducibly shown this capability in animal models. Efforts have first made use of $\gamma$-RV derived from
the Moloney murine leukemia virus (M-MuLV). The first M-MuLV vectors containing a human β-globin gene and its promoter were reported by the Mulligan and Nienhuis laboratories. However, β-globin expression was erythroid specific but well below a possible therapeutic effect. Incorporation of core LCR elements resulted in low-titer γ-RV that were also highly unstable with multiple rearrangements of the transferred proviral structures. Reducing the size of the LCR to minimal elements is unsatisfactory as β-globin expression levels are too low. Leboulch et al. identified untoward polyadenylation and splicing of the genomic viral RNA before packaging as the main mechanisms of both low titers and provirus rearrangements (internal splicing and polyadenylation). LCR elements, the promoter, and the actual globin gene were placed in reverse orientation to avoid splicing of the bona fide introns before packaging, which resulted in the unmasking of consensus polyadenylation and splicing signals along the vector genomic viral RNA. A small internal deletion of sequence repeats within the second (minigene), together with site-directed mutagenesis eliminating those sequences, resulted in stable proviral transmission. Sadelain et al. achieved a similar result by applying the same internal deletion within the second intron while permuting LCR elements, possibly resulting in a conformational change in the viral genomic RNA that also inhibited untoward splicing. In spite of these advances, vector-encoded β-globin remained below therapeutic levels, and transduction of HSCs by γ-RV was suboptimal in vivo.

Grants from the National Institutes of Health (NIH) were awarded in the mid-1990s to focus on making further progress in this area. Sadelain and Leboulch (together with R. Nagel, I. Mondon, C. Eaves, and K. Humphries) were awarded grants to make further progress in this area. Sadelain and colleagues published the first correction of murine β-thalassemia by an LV containing the β-globin mini-gene described above, although with substantially larger LCR elements than those incorporated in previous γ-RV (LV referred to as TNS9). Leboulch and colleagues published the first correction of transgenic mouse models of SCD by making use of their own vector, also containing the β-globin mini-gene together with similarly larger LCR elements (644 bp for HS2, 845 bp for HS3, and 1153 bp for HS4). Importantly, this LV contains the antisickling β^AcT87Qβ-globin gene. Human CD34+ cells transduced with a SIN version of this vector generated long-term hematopoietic reconstitution in immunodeficient mice, indicating effective transduction of human HSCs. This vector was modified further in the Leboulch lab to yield HPV569 and BB305 vectors, which have become the basis for our own clinical trials described in this review. We and other groups have subsequently published other β-globin- or γ-globin-based LVs and reported efficient transduction of mouse HSCs and high levels of β-globin expression.

REGULATORY APPROVAL PROCESS IN THE UNITED STATES AND THE EUROPEAN UNION

In spite of existing regulatory frameworks for gene therapy projects, there are still many unknowns, in part because of the lack of precedents. Innovative regulatory science can help foster a supportive ecosystem for gene therapy products and accelerate their development in a sustainable manner. An example of such a framework is the adaptive biomedical innovation framework.

Frequent, science-based, transparent, and proactive interactions with regulators can also contribute to the overall development strategy for gene therapy products by reducing regulatory uncertainty. The majority of the regulatory mechanisms that exist to accelerate the development of medicinal products, including gene therapy products, require (1) targeting a serious or life-threatening condition with significant unmet medical need, (2) having the potential for outstanding efficacy with an acceptable safety profile, and (3) having a robust development plan. A clear mechanism of action and early proof-of-concept studies are also helpful.

Typically, the first interaction with regulatory agencies in the development of a gene therapy product is to discuss the nonclinical development (traditionally referred to as pharmacology and toxicology) and the design of the planned first-in-human study. In the United States, this first in-
teraction is a pre–Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA). In the European Union (EU), this first interaction can be a presubmission meeting before filing a clinical trial application (CTA) with national authorities and/or a scientific advice meeting with the European Medicines Agency (EMA). In addition, “pre-pre-IND” informal discussions with FDA and meetings with the EMA Innovation Task Force can be useful to discuss the early development of very innovative products, including innovative gene therapy products. Seeking orphan designation for products developed for rare diseases (defined as fewer than 5/10,000 affected individuals in the EU\(^\text{118}\) and fewer than 200,000 prevalent cases in the United States),\(^\text{119}\) as well as seeking EU gene therapy\(^\text{120}\) can also be helpful early on for sponsors to define their products and their active substance, clarify their mechanism of action, and outline their potential for significant clinical benefit.

Clinical trials are regulated under Directive 2001/20/EC in the EU and under 21 CFR Part 312 in the United States. In the EU, a new regulation\(^\text{121}\) will come into force in 2016 that will replace the current directive. This regulation should streamline the process and allow for centralized submissions via a new electronic portal system to one reference member state. For gene therapy products, seeking approval to initiate a clinical trial in the EU currently requires filing a CTA including an investigational medicinal product dossier (IMPD) in each member state involved, and requires filing a genetically modified organism (“GMO”) submission sometimes in advance of the CTA. GMO submissions for gene therapy products are cumbersome and often unclear. In the future, specific applications customized for gene therapy medicinal products should be created and these should be managed by the same regulatory agencies receiving the CTA applications. In the United States, filing of an IND application is required. INDs follow the common technical dossier (CTD) format of the international conference harmonization (ICH). IMPDs headings are also consistent at a high level with the CTD organization (Fig. 2).\(^\text{122}\) IMPDs and INDs must contain information on manufacturing and quality, on the nonclinical studies conducted, and on the planned clinical trial, including a protocol and Investigator’s Brochure. For gene therapy products, filing a pediatric investigational plan (PIP) with EMA early in the development is advisable if the targeted condition affects pediatric patients. During this process, sponsors can receive advice on their preliminary long-term development plans.

Other key regulatory mechanisms that can be leveraged to accelerate the development of gene therapy products include seeking fast-track desig-
nation or breakthrough therapy designation in the United States. In the EU, in addition to scientific advice, applying for an EMA nonclinical and quality/manufacturing certification procedure should be considered (for small and medium-size enterprises), as well as seeking the recently created priority medicines (PRIME) designation, and leveraging the flexibility of the risk-based approach and of the advanced therapy medicinal product (ATMP) Regulation No. 1394/2007/EC, particularly for the quality/manufacturing development.

In the specific case study of HPV569 and BB305 drug candidates, a number of above-mentioned existing regulatory mechanisms were used to support and accelerate development, with an emphasis on evaluating early the entire life-span of the product in a creative way, including leveraging the potential of real-world evidence and “Safe Harbor” discussions with multiple stakeholders, including patients’ representatives.

Looking forward, in order to obtain marketing authorization, a biological license application (BLA) must be submitted to the FDA in the United States in accordance with 21 CRF Part 601. In the EU, a marketing authorization application (MAA) must be submitted to the EMA in accordance with Directive 2001/83/EC and the advanced therapy medicinal product (ATMP) regulation 1394/2007/EC.

Gene therapy products provide unique opportunities to contribute to the evolution of regulatory science because of their transformative efficacy potential, their increasing complexity, and their pending individualized nature.

**HPV569 AND BB305 VECTOR DEVELOPMENT**

The HPV569 lentiviral vector was assessed in the first human trial LG001

The original LVs we used to achieve long-term correction of SCD and β-thalassemia in mice comprised (1) HIV1’s RRE and central polypurine tract; (2) the human β-globin gene, in reverse orientation, either wild-type or with the βT87Q mutation; (3) the human β-globin promoter, and (4) a mini-LCR composed of HS2, HS3, and HS4 of 644, 845, and 1153 bp length, respectively.

To prepare for human clinical trials, safety modifications were made to the original vector, as follows, to yield the vector referred to as HPV569. These include mutating the GAG gene and deletion of the viral enhancer and promoter elements in the U3 region of the 3’LTR to generate a SIN vector (Fig. 3). The SIN modification reduces the likelihood of propagation of replication-competent recombinant LV in the vector producer and target cells, decreases the risk of mobilization of the vector genome upon HIV secondary infection, and reduces the residual activation of cellular oncogenes by enhancer/promoter activities of integrated LTRs. Another modification has concerned the U5 region of the 3’LTR, which was replaced by an artificial polyadenylation/termination signal derived from the rabbit β-globin gene. This latter modification yielded higher viral titers for the SIN versions of the HPV569 vector because of more efficient polyadenylation/termination of the viral transcript. In an effort to protect transduced cells

**Figure 3.** Diagram of the HPV569 β-globin (βA-T87Q) lentiviral vector. The 3′ β-globin enhancer, the 372 bp IVS2 deletion, the βA-T87Q mutation (ACA[Thr] to CAG[Gln]), and DNase I hypersensitive sites (HS) 2, HS3, and HS4 of the human β-globin locus control region (LCR) are indicated. Safety modifications, including the 2 stop codons in the Watson packaging signal, the 400 bp deletion in the U3 of the right HIV LTR, the rabbit β-globin polyA signal, and the 2×250 bp cHS4 chromatin insulators, are indicated. In the BB305 lentiviral vector, U3 promoter/enhancer has been replaced by cytomeglovirus (CMV) promoter/ enhancer and the 2×250 bp cHS4 insulator elements have been removed. cPPT/flap, central polypurine tract; HIV LTR, human immunodeficiency type-1 virus long terminal repeat; ppt, polypurine tract; RRE, Rev-responsive element; βp, human β-globin promoter.
against cis activation of adjacent genes by enhancer activities present within the \( \beta\)-globin LCR,\(^{157} \) two copies of the 250 bp core elements of the chicken \( \beta\)-globin chromatin insulator (chicken \( \beta\)-globin locus DNase I hypersensitive site 4: cHS4) were inserted in place of the deleted U3 region of the vector.

The HPV569 vector\(^{109} \) was produced at clinical grade\(^{68} \) and used to evaluate therapeutic efficacy and safety in a mouse model of \( \beta\)-thalassemia.\(^{138} \) The gene-corrected mice showed normalization of their phenotype. Consistent with other LV studies,\(^{139,140} \) the HPV569 vector was shown to favor targeting of transcription units (\( \sim 70\% \)) and gene-dense regions. Importantly, no enrichment of integration sites within proto-oncogenes was found posttransplantation, and no relationship was seen between the proximity of integration sites to oncogenes and site abundance in mice.\(^{138} \) A variety of complementary efficacy and safety studies were performed in human CD34\(^+ \) cells from patients and in several mouse models before filing a CTA dossier with the French regulatory agency, as described in the section Regulatory approval process in the United States and the European Union. The first clinical trial with the HPV569 drug product candidate vector (LG001) was initiated in 2006 in France. Three subjects with \( \beta\)-TM were treated and one (subject No. 1003) became transfusion independent (see details below).\(^{141} \)

The BB305 lentiviral vector

Although the LG001 trial brought the proof-of-principle of clinical efficacy in a human patient (subject No. 1003), partial clonal dominance, which subsequently resulted, was observed upon vector integration within the \( \text{HMGA2} \) gene. This integration triggered abnormal splicing of the endogenous \( \text{HMGA2} \) RNA using a cryptic acceptor site within the cHS4 insulator core in the left LTR. Studies performed in mouse samples showed that most of the integrated provectors had lost one of the two 250 bp cHS4 insulator cores at each end.\(^{138} \) This phenomenon was observed in subject No. 1003 as well.\(^{141} \) Data reported by several contributors also showed that inclusion of cHS4 chromatin insulator elements in the \( \text{3}' \)LTR of LVs reduced their titers and transduction efficacy for human CD34\(^+ \) cells.\(^{142–144} \) Moreover, their presence had limited efficacy on transgene expression in human hematopoietic cells \textit{in vitro} and \textit{in vivo},\(^{144} \) while the protection provided was dependent on the location of cHS4 integration in the genome.\(^{145} \) For all these reasons (decreased titers and transduction efficiency, insulator loss, untoward splicing, and limited enhancer blocking activity), removal of the cHS4 insulator from our HPV569 vector was warranted.

In addition, we decided to replace the Tat-dependent U3 promoter/enhancer of the \( 5' \)LTR by that of the cytomegalovirus (CMV) (Fig. 3) in order to further increase the titer of the vector.\(^{105} \) Overall, the modified vector, referred to as the BB305 vector,\(^{110} \) is identical to HPV569 after chromosomal integration, except for the absence of the cHS4 insulator (Fig. 3). In plasmid form, however, as used in producer cells, the CMV promoter now drives transcription instead of the \( 5' \)LTR.

The new-generation BB305 vector was produced, purified, and tested on human CD34\(^+ \) cells as well as in a mouse model of \( \beta\)-thalassemia.\(^{110} \) Side-by-side comparison of HPV569 and BB305 showed that the vector changes resulted in both increased vector titers (3–4-fold) and increased transduction efficiency (2–3-fold). Comprehensive toxicological mouse studies and vector comparison showed \( \beta\)-thalassemic phenotype correction with no evidence of toxic effect related to any of the vectors, and similar integration patterns (mostly within RefSeq genes), without any sign of clonal outgrowth or \textit{in vivo} selection.\(^{110} \) \textit{In vitro} immortalization (IVIM) assays, developed by the Baum lab,\(^{146} \) were run in order to evaluate the risk of hematopoietic cell transformation upon vector integration. Both vectors (HPV569 and BB305) exhibited a strongly reduced risk of immortalization of murine hematopoietic cells as compared with control retroviral vectors, and LVs containing the strong SFFV viral promoter.\(^{110} \)

VECTOR AND DRUG PRODUCT MANUFACTURING

Production of lentiviral vectors

Guidance on development and manufacturing of LVs, which are considered starting materials by both U.S. and EU regulatory agencies when used for \textit{ex vivo} transduction, is provided by FDA and EMA. This guidance provides recommendations for LV design, manufacturing, and characterization, including transducing activity, LV particle quantification, and testing for replication-competent lentiviruses (RCLs). bluebird bio has developed a GMP manufacturing process for large-scale production (>40 liters) of third-generation VSV-G-pseudotyped HIV-1-based LVs. Clinical-grade vesicular stomatitis virus glycoprotein-pseudotyped lentiviral particles are produced by a plasmid-based co-transfection method. Purification is done by chromatography and buffer is exchanged by ultrafiltration before final filtration according to
published protocols. This method is used to produce large-scale clinical-grade LV lots to support our clinical trials.

Release tests performed on the manufactured LV include potency and identity, safety, and purity. The LV potency is determined using assays that measure both the concentration of viral particles and infectious titer. The concentration of vector particles is assessed by measuring the HIV-1 p24 antigen. The titer is defined as the number of functional transduction units per milliliter (TU/ml). Vector infectivity (or specific transducing activity) is defined as the ratio between transduction unit per milliliter and the concentration of p24 (TU/ml)/(ng/ml). This ratio gives a reliable parameter to evaluate the quality of the vector preparation. High-quality vector preparations with an infectious titer >10^8 TU/ml and a particle/infectious ratio between 100 and 500 are obtained.

The ability of transduced cells to produce the therapeutic β^T87Q-globin is verified after erythroid differentiation of transduced CD34+ hematopoietic cells. It is assessed by reverse-phase HPLC analysis of globin chains in differentiated erythroid cells. The therapeutic β^T87Q-globin can be easily distinguished from the normal β-chain, as well as from the β^E and β^S polypeptides.

The generation of RCL is highly improbable because of the multiplasmid packaging system and the U3-deletion. Nevertheless, RCL testing is performed. It relies upon the permissive cell line C8166-45, allowing the amplification and the detection of replicative-competent particles.

**Drug product (genetically modified CD34+ cells)**

Once subjects have been screened and eligibility has been determined, autologous hematopoietic CD34+ cells are procured either by apheresis of mobilized peripheral blood cells (for β-TM subjects) or by bone marrow harvest (for subjects with SCD). Multiple harvests may be undertaken if needed to meet the minimum cell dose required for drug product manufacturing and untransduced backup. Mobilization is performed with filgrastim, a recombinant form of granulocyte-colony stimulating factor (G-CSF), in combination with plerixafor. The combination of plerixafor and filgrastim may be the most effective mobilization strategy for subjects with β-thalassemia. Apheresis is performed on the fifth day of mobilization. The objective is to collect sufficient cells for both manufacturing and for rescue therapy. After procurement, the CD34+ cell population is enriched via purification. A portion of the product is cryopreserved for rescue therapy. CD34+ cells are grown in serum-free medium supplemented with recombinant human cytokines stem cell factor (SCF), thrombopoietin (TPO), and FMS-like tyrosine kinase receptor-3 (Flt3-L) for approximately two days. The cells are then incubated for an additional day for the lentiviral transduction step. After transduction, a portion of the cells and supernatant are removed for release testing. The reminder of the cells is cryopreserved. After the completion of release testing and disposition, the drug product, defined as CD34+ hematopoietic stem cells transduced with the BB305 LV, is infused after the patient has undergone myeloablative conditioning.

**CLINICAL TRIALS: INTERIM RESULTS FROM FRANCE**

The HPV569 and BB305 vectors are designed to be used as a single product for the gene therapy of the β-hemoglobinopathies (SCD and β-TM). Vector design is intended to overcome the deficit of β-globin chains in β-thalassemia and to provide anti-HbS polymerizing activity in SCD. The HPV569 vector is the first vector to have been tested worldwide in an approved human trial for the gene therapy of the β-hemoglobinopathies, with the first patient transplanted with transduced cells in 2006.

The French trials led the way in the testing of the HPV569 and BB305 drug products and are the primary focus of this review article. The BB305 program has now expanded internationally, and initial results are summarized in Table 1 and in the section Multicenter U.S. and international trials for β-TM (HGB-204) and SCD (HGB-206) with the BB305 drug product. Other ongoing trials of other gene therapies for hemoglobinopathies are summarized in Table 2.

**Study design and pretransplant conditioning**

Clinical studies of HPV569 and BB305 drug products run in France are nonrandomized, open-label, single-dose, phase 1/2 studies and only enroll patients with no sibling donor. The first trial performed, with regulatory approval obtained in 2006, was termed LG001 and aimed to assess the HPV569 drug product, as described in the section. “The HPV569 lentiviral vector was assessed in the first human trial LG001” above, in 10 subjects with β-TM or severe SCD. After 3 subjects had been treated, the HPV569 vector was replaced with the improved BB305 vector and manufacturing thereof, and a new clinical trial protocol, termed HGB-205, was implemented to treat the remaining 7 subjects. The
HGB-205 study is currently ongoing in France for β-TM and SCD.

In addition to the characteristics of the clinical-grade vector (high-titer, high purity of the manufactured lot, intrinsic therapeutic globin expression properties), key parameters to success include (1) the dose of CD34+ cells infused, (2) the mean vector copy number (VCN) in CD34+ cells preinfusion, and (3) efficient myeloablative conditioning. Because there is little convincing evidence in animal models and clinical trials that effective lentiviral gene transfer to HSCs can be achieved with a high degree of sustained chimerism for vector-bearing cells in the absence of extensive myeloablation, when a CD34+ cell dose similar to that applicable to human autologous settings is used, we decided to apply a full dose of myeloablative agent with intravenous (IV) busulfan as pretransplant conditioning regimen. However, the additional use of immunosuppressive agent (e.g., cyclophosphamide) is not required in this autologous setting. Monitoring of busulfan conditioning to optimize HSC transplantation is an important component of the success156 and is meticulously performed. When the drug product manufacture is complete, the subject receives myeloablative conditioning with IV busulfan at a starting dose of 3.2 mg/kg/day for 4 days with pharmacokinetics analysis. The dose and schedule of busulfan is monitored daily and may be adjusted based upon busulfan plasma levels in order to maintain appropriate levels for myeloablation (AUC exposure of 4500–5000 [\mu \text{M} \cdot \text{min}/\text{day} for a daily dosing regimen, over 4 days). After busulfan washout for several days after the end of IV busulfan administration, the drug product is infused. The subject remains hospitalized until engraftment occurs (absolute neutrophil count [ANC] ≥0.5 × 10^9/liter for 3 consecutive days) and the patient is medically stable. Subjects are followed monthly for the first 6 months posttransplant, and then every 3 months through 24 months posttransplant. Subjects are then enrolled in a long-term follow-up study for an additional 13 years.

Endpoints. The primary study objective is to assess the safety, tolerability, and success of engraftment with autologous CD34+ HSCs transduced with the vectors encoding the human \( \beta^{\text{A-T87Q}} \)-globin gene after conditioning with intravenous busulfan in subjects with β-TM and severe SCD. The primary outcome measures are success and kinetics of HSC engraftment, incidence of transplant-related mortality through 100 days posttreatment, overall survival, detection of RCL, characterization of any events of insertional mutagenesis, and monitoring of laboratory parameters, and frequency and severity of clinical adverse events (AEs).

Secondary endpoints include therapeutic globin (HbA\(^{\text{T87Q}}\)) expression quantified by HPLC analysis, VCN levels in peripheral blood (and in bone marrow, if collected), and RBC transfusion requirements posttransplant. They also include the assessment of dyserythropoiesis for β-TM subjects and VOC and ACS frequencies for SCD subjects.

Inclusion criteria. All subjects must be between 5 and 35 years old. They must have transfusion-dependent (≥100 ml/kg/year of packed RBCs for β-TM) or severe SCD, confirmed by Hb studies. Subjects must be eligible for AHSCT based on institutional medical guidelines, but without a suitable, willing HLA-identical sibling donor. In addition, subjects with SCD must have failed to achieve adequate clinical benefit after hydroxyurea treatment for at least 4 months unless this treatment was not indicated or not well tolerated, and have a history of 1 or more of the following poor prognostic risk factors: recurrent VOC, ACS (at least 2 episodes), significant cerebral abnormality on magnetic resonance imaging (MRI), stroke, antierythrocyte alloimmunization (>2 antibodies), presence of SCD cardiomyopathy documented by Doppler echocardiography, or osteonecrosis of 2 or more joints.

All subjects must have been treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history. Sperm preservation or testis or ovary biopsy is offered to subjects enrolled on the study. All subjects or their parents or guardians must provide written informed consent.

Exclusion criteria. Subjects meeting any of the following criteria cannot be enrolled in the study: (1) availability of HLA-identical sibling hematopoietic cell donor, (2) clinically significant, active bacterial, viral, parasitic, or fungal infection, (3) prior or current malignancy, myeloproliferative disorder or immunodeficiency, (4) contraindication to anesthesia for bone marrow harvesting, (5) white blood cell count lower than 3 × 10^9/liter and/or platelet count lower than 120 × 10^9/liter, and (6) history of major organ damage.

Trial results to date

The LG001 and HGB-205 were the first gene therapy studies worldwide to treat β-TM and SCD subjects, respectively, achieving the first conversion to long-term transfusion independence of a β-TM subject15,141,157,158 and the first evidence of clinical benefit in SCD.159
\(\beta\)-TM patients in the first French trial LG001 with HPV569 drug product. Four subjects with \(\beta\)-TM were enrolled, 3 of whom were treated between 2006 and 2011, under the LG001 protocol. Subject 1002 was 29 years old with \(\beta^{+}/\beta^{a}\) genotype and received a dose of 0.93 \(\times\) 10^6 cells/kg with a mean VCN of 1.3. Subject No. 1003 was 18 years old with \(\beta^{E}/\beta^{0}\) genotype and received a dose of 3.9 \(\times\) 10^6 cells/kg with a mean VCN of 0.6. Subject 1004 was 22 years old with \(\beta^{S}/\beta^{0}\) genotype and received a dose of 4.3 \(\times\) 10^6 cells/kg and a VCN of 0.3. Transfusion was uneventful in all subjects. Transduced cells did not successfully engraft in subject 1002, although gene marking was detectable for a few months; this subject received backup hematopoietic cells for rescue and remains transfusion dependent. Neutrophil engraftment was reported for subject No. 1003 at day +27 and for subject 1004 at day +22 postinfusion. The HPV569 drug product was well tolerated, with no nonhematologic serious AE and no drug product-related AEs reported. In addition, no subject has developed vector-derived RCL, leukemia, or lymphoma.

Clinical benefit of treatment with HPV569 drug product was observed in 1 of the 2 treated subjects who did not receive backup cells. Subject No. 1003 sustained clinical benefit as evidenced by long-term transfusion independence that was achieved approximately 1 year posttransplant\(^{15,141}\) and sustained through approximately 8 years posttransplant. The hemoglobin level stabilized 1.5 years posttreatment, and the mean VCN per myeloid cell was close to 0.2. A detailed report on this subject after 33 months of follow-up has been published.\(^{15,141}\) After approximately 7 years of transfusion independence, this subject received a few transfusions to address symptoms of anemia. Ongoing follow-up will determine whether or not periodic transfusion support will again be required. His total hemoglobin and levels of HbAT87Q transgenic hemoglobin have remained generally consistent from years 2 through 8 posttransplant at around 8 g/dl total Hb of which 30% is HbAT87Q.

Integration-site analysis revealed the relative dominance of a clone bearing the vector inside intron 3 of the \(HMGA2\) gene, the proportion of which reached a maximum representation of \(\sim 30\%\) of the transduced myeloid cells (i.e., \(\sim 4\%\) of hematopoietic cells) 15 months posttransplantation. Molecular analyses revealed that the integrated vector had caused transcriptional activation of the \(HMGA2\) promoter in erythroid cells. Furthermore, a cryptic splice acceptor site (GTAT(C)\_6\_AG), located within the cHS4 insulator core of the 5'LTR, generated a truncated mRNA containing \(HMGA2\) exons 1, 2, and 3. Cleavage/polyadenylation occurred within the adjacent R region of the 5'LTR that leads to increased stability of the RNA because of deletion of the Let7 microRNA binding sites (located in exon 5) and an excess of truncated \(HMGA2\) mRNA. The clone has remained under homeostatic control, with a peak at \(\sim 4\%\) of hematopoietic cells 4 years after transplantation, gradually decreasing to approximately 1% of total nucleated blood cells at 5 years posttransplant.\(^{158}\) The clone is absent from lymphocytes. Despite declining levels of this clone, the amount of \(\beta^{T87Q}\)-globin has remained stable, indicating that the observed therapeutic benefit is not dependent on this specific clone. The insertion of viral vectors in the \(HMGA2\) gene has been observed in other gene therapy studies, with no case of leukemia or lymphoma related to this insertion site in any patient.\(^{158,160–162}\)

\(\beta\)-TM and SCD patients in French trial HGB-205 with BB305 drug product. As of November 2015, four subjects with \(\beta\)-TM and one subject with SCD have been treated with BB305 drug product under the HGB-205 protocol. Initial results have been presented at scientific meetings but not yet published, and the trial is ongoing.\(^{157–159}\) All of the four treated \(\beta\)-TM subjects have so far become transfusion independent, and the treated SCD subject shows early clinical benefit.

**MULTICENTER U.S. AND INTERNATIONAL TRIALS FOR \(\beta\)-TM (HGB-204) AND SCD (HGB-206) WITH THE BB305 DRUG PRODUCT**

Additional subjects with \(\beta\)-TM and SCD are currently being treated under the HGB-204 and HGB-206 protocols, in two separate international and U.S. studies (Table 1).\(^{163,164}\) Early initial results have been presented at scientific meetings but not yet published.

**CONCLUSIONS**

Gene therapy for hemoglobin disorders has made major progress, from early discovery of \(\beta\)-globin regulatory elements; development of LVs, including the HPV569 and BB305 vectors described here; efficient transduction of hematopoietic stem cells; proof-of-principle of efficacy in
mouse models; the first conversion to multyear transfusion independence of a patient with \( \beta \)-TM; and early clinical benefit now observed in SCD.

Successfully implementing a gene therapy strategy for the \( \beta \)-hemoglobinopathies involves an integrated approach of regulatory, manufacturing, and clinical trial design, and execution. The promise of bringing this therapeutic modality to a large number of patients will require the successful industrialization and commercialization as well as regulatory product approval.

To date, no serious adverse effects have been attributed to \( \text{ex vivo} \) LV-based HSC gene therapy for hemoglobinopathies, but long-term data in a larger number of patients are needed to assess the risks fully. Current vectors are designed to minimize the possibility of genotoxicity, including oncogenesis, but this risk cannot yet be conclusively quantified or excluded. Ongoing and future clinical studies will allow for a more complete understanding of the benefit–risk profile of this therapeutic approach. Implementation of gene therapy for \( \beta \)-TM and SCD to a large extent will depend on the benefit/risk/cost ratios.

ACKNOWLEDGMENTS

We thank Eliane Gluckman (Saint-Louis hospital, Paris, France), the principal investigator at the beginning of the LG001 study; Françoise Bernaudin (CHIC, Créteil, France) for contributions to study design and for clinical care; and Olivier Hermine and Felipe Suarez (Necker Hospital, Paris), the transplanters for the HGB-205 study. We thank Christof von Kalle, Manfred Schmidt (National Center for Tumor Disease, Heidelberg, Germany) and Frederic Bushman (University of Pennsylvania, PA) for vector insertion site analyses. We thank Laure Caccavelli (Necker hospital, Paris, France) and the bluebird bio France team (CEA, Fontenay aux Roses, France) for technical assistance. We thank Philipp Gregory, Sandeep Soni, Kate Lewis, Gabor Veres, Michael Paglia, John Piercye, and Tim Douros (bluebird bio, Cambridge) for manuscript proofreading. The work was supported by an Industrial Chair from France’s Agence Nationale pour la Recherche (ANR) awarded to Philippe Leboulch. bluebird bio is the sponsor of the clinical trials and provided funds to Necker Hospital, Assistance Publique-Hôpitaux de Paris.

AUTHOR DISCLOSURE

O.N. and A.-V.E. are employees of bluebird bio, Inc. Y.B., P.L., and E.P. have financial relationships with bluebird bio, Inc. All other authors have no competing interests to disclose.

REFERENCES


66. Maurer HS, Behrman RE, Honig GR. Dependence of the oxygen affinity of blood on the presence


119. U.S. Food and Drug Administration. Developing products for rare and serious conditions. www.fda.gov/ForIndustry/DevelopingProductsForRareDiseasesConditions/default.htm


126. FDA. Title 21—Food and Drugs Chapter I—Food and drug administration department of health and human services subchapter F—Biologics—Part 601 Licensing. www.accessdatafda.gov/scripts/cdrh/cfdocs/cfr/CFRSearch.cfm?CFRPart=601


Received for publication January 14, 2016; accepted after revision January 21, 2016. Published online: January 22, 2016.